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1 Introduction
The number of individuals suffering from one of the various chronic diseases, which
according to the World Health Organization (WHO) may also be referred to as no
communicable diseases, has been increasing [1]. The significant increase in the
average life expectancy at birth in recent years is an important and contributory
factor, resulting in a greater focus on the disease in the elderly, who in future
will be the large part of the population. These diseases are largely responsible
for the expense of national health systems, which nowadays face major problems
with scarce financial and human resources. From the point of view of the chronic
patient, the expenses with the disease are high due to the medication costs and
continuous monitoring and support that the disease demands [2]. Chronic patients
are considered the main responsible for the increasing use of medical, hospital and
emergency services. Thus, a special care that considers monitoring certain physical
and biological parameters associated with the disease is required [3].
So, the need to find solutions to provide healthcare where good management
of chronic diseases is performed, addressing the problem of the shortage of health
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professionals by effectively allocating the available resources [4], is growing and
it is believed that passes through telehealth devices and/or systems [5]. Telehealth,
e-health, m-health and telemonitoring are quickly evolving and are already part of
health systems. However, in the future, telemonitoring may become critical in the
treatment of chronic diseases [3].
Telemonitoring consists in accomplishing the distant monitoring of patients, i.e.,
monitoring them remotely from the comfort of their home or beyond it [6]. Thus,
there is an automonitoring of biological and physical parameters of the patient
outside the hospital environment performed by itself or by a health provider, and the
data is transmitted to the health care systems using information and communications
technology (ICT).
The use of telemonitoring devices and systems can provide a safe and effective
monitoring of these patients. The measurement of physical and biological parame-
ters essential for the analysis of the evolution and treatment of the disease prescribed
by the health professionals allows them to evaluate the data and take decisions to
change or maintain prescriptions or health care for the monitored patient [4, 7].
Telemonitoring combines several advantages for patients with chronic diseases
as well as for health systems. For the patient, telemonitoring allows the promotion
of a better self-control that results in a better quality of life [2]. In the background,
it allows the early detection of warning signs that consequently decrease the
hospitalizations of these patients [4]. For the healthcare systems, the lack of health
professionals and the lack of financial resources can be diminished by telemonitor-
ing these patients. Health institutions will in future experience difficulties in caring
for patients and their hospitalization. The growing number of patients is related also
to the increasing trend of average life hope [4].
It is perceived that there is a problem in the health systems that will follow a
worldwide worsening trend in the near future. The part of this problem can be
surpassed with the growth of telemonitoring in the health sector, and particularly
fostering the telemonitoring physical and/or biological parameters of patients with
different chronic diseases.
This paper describes the evaluation carried out concerning the current status
of telemonitoring devices and systems existing in the market and in some cases
in the development phase. Their technical specifications, characteristics and their
advantages for patients and health systems are described. In addition, the future
trend for the development of this type of devices and system is analysed. Proposals
for the implementation of new telemonitoring devices and systems for the support
and management of chronic diseases are performed.
2 Methods
It is essential to introduce telemonitoring devices and systems into the daily life
of chronically ill patients. As this condition is becoming a reality, a research
and a description of some of market-available telemonitoring devices and systems
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applied to different chronic pathologies is performed. The selection of chronic
diseases described within the paper was performed according to two criteria: (1)
prevalence of chronic diseases, and preference was given to those with the highest
incidence in the population; (2) frequency of information found in academic and
scientific databases, such as PubMed, IEEE and B-on. Additionally, the technical
specifications were gathered from the web pages of companies manufacturing or
distributing telemonitoring devices and systems referenced in reports prepared by
the Market Reports Center.
Proposals are performed to improve the technical specifications of the future
telemonitoring devices and/or systems based on the ones existing in the market.
3 State of the Art on IoT Telemonitoring Medical Devices
The telemonitoring devices and systems discussed in this article were HealthGO
Mini, VITALS360®, CareHomePod and HomePod, iSpO2®, EQ Connect™,
eNephro, Prototype Device, eCareCompanion, Genesis Telemonitor, Honeywell
HomMed, TCare Cardio Monitor and Smartheart™. These telemonitoring devices
and systems are applied to chronic diseases such as Diabetes mellitus, Chronic
Obstructive Pulmonary Disease (COPD) and Asthma, Chronic Kidney Disease,
Thromboembolic Diseases and Heart Failure.
3.1 Telemonitoring Devices Used in Diabetes Mellitus
Diabetes mellitus is characterized as being a metabolic disease in which there is
hyperglycaemia resulting from defective insulin secretion, insulin action or both.
Chronic hyperglycaemia of diabetes is associated with long-term damage, such as
dysfunction and failure of various organs, especially eyes, kidneys and heart [8].
According to the International Diabetes Federation (IDF) in 2011, 35 million adults
had Type 1 or Type 2 diabetes. The estimate for 2030 is that there are 43 million
adults with diabetes [9].
Diabetes management in Europe alone entails huge costs for health systems. In
2011, 89 million euros were spent on the treatment of diabetes and its complications,
with no indirect costs being accounted for, which can increase the associated costs
dramatically [9]. In the year 2013, IDF accounted for about 206 million diagnosed
diabetics globally. The costs associated with Type 2 diabetic patients alone are about
two to three times higher compared to a person of the same sex and the same age
without the disease. Approximately 80% of the costs that this disease brings to
health systems are the treatment of complications resulting from poor management
of the disease [10].
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According to IDF, the costs associated with diabetes will increase greatly due
not only to the expected increase in the number of patients but also to the associated
costs due to complications caused by poor management of the disease [9].
Monitoring glycaemic control in diabetic patients is essential. This procedure,
repeated throughout the day along with taking the correct medication is essential
to avoid complications of the disease. These patients have direct contact with the
specialty doctor on average every 3 months or every 4 months, where adjustments
are made to the therapy. In the intervals of these consultations, the dosages of
medication may have to be changed to an efficacy of disease management. This
is made difficult by the fact that the patient does not have the medical advice to do
so [10].
Following is a set of commercially available diabetes mellitus telemonitoring
devices. The devices described are HealthGO Mini, VITALS360® and Care-
HomePod and HomePod. The CareHomePod is used in multi-resident homes and
the HomePod is used in singular-resident homes. All devices have the portable
advantage, allowing patients to take them in the event of a need to travel. The
HealthGO Mini and CareHomePod and HomePod work as platforms that receive
data collected by other devices, in this case, the blood glucose metre that diabetic
patients use to obtain the blood glucose value that they connect with the platform
(HealthGO Mini) via Bluetooth or USB and with the tablet (CareHomePod and
HomePod) via Bluetooth. In the case of the VITALS360® device, it already has
a built-in blood glucose metre that allows the blood glucose test to be performed
directly on the device [11–13].
The process of obtaining the glycaemic value is invasive in all devices and
platforms; being through the puncture to obtain a drop of blood that is placed
on a test tape that is previously placed in the blood glucose metre. After this
process, the glycaemic values obtained are sent through Wi-Fi to databases of each
device that allow the analysis of these data by specialized health professionals
who subsequently make the decision how to act. The device-to-patient interface
is simple on all devices but customizable to the patient only VITALS360® and
CareHomePod and HomePod have this feature [11, 13, 14]. Table 1 compares the
technical specifications of telemonitoring devices and systems found for Diabetes
mellitus disease.
Table 1 Comparison of technical specifications of telemonitoring devices used in Diabetes
mellitus
Device 1 Device 2 Device 3
Designation HealthGO Mini VITALS360® CareHomePod; HomePod
Portability Yes Yes Yes
Invasiveness Yes Yes Yes
Interface Not customized and simple Custom and simple Custom and simple
Connectivity BluetoothUSBWi-Fi Wi-Fi BluetoothWi-Fi
Interoperability No No No
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It is concluded that all the described devices present very similar technical
specifications, being overall only distinguished by the functionalities related to the
connectivity, which are fundamental for any telemonitoring device, as well as for
the man–machine interface. Interoperability is the missing technical specification in
the three telemonitoring devices and systems analysed. However, as long as there is
no international regulation that mandates and imposes manufacturers to provide this
functionality in their devices, all will continue to use closed proprietary systems.
It is important to remember that interoperability between systems and devices will
have to be followed by strict legal and regulatory policies and standards related to
data encryption to ensure their confidentiality. Some steps are taken in this direction
by the Food and Drug Administration (FDA) in the United States of America (USA)
as well as the European Commission (EC) in the European Union (EU).
3.2 Telemonitoring Devices Used in COPD and Asthma
Chronic Obstructive Pulmonary Disease (COPD) is a very common disease and
is characterized by a progressive decrease in lung capacity and acute respiratory
exacerbations [15]. In COPD there is a limitation of progressive respiratory flow,
which may be partially or totally irreversible, associated with a chronic inflamma-
tory response that increases harmful particles or gases in the airways and lungs [16].
In this disease, the loss of respiratory muscle function and airway obstruction is
progressive [16], resulting in frequent hospital admissions, incapacity for the patient
with this disease and also depression [17].
These patients suffer with the gradual worsening of some symptoms and also of
lung function for a few days, such as exacerbations, sinus tachycardia, dyspnoea
and hypoxemia. The early recognition by patients of these serious symptoms is
not always achieved in order to avoid hospitalization. These symptomatologic
events contribute significantly to a worsening of the disease, by deteriorating the
respiratory health of the patient, and consequently also contribute to a lower quality
of life for the patient [15, 16].
It is estimated that by 2020 the costs associated with the disease in the USA
reach $49 billion annually. These costs are mostly due to hospital admissions due to
exacerbations [18].
Asthma, which can be referred to as a form of COPD, is a disease that presents
problems on a global scale and affects both the quality of life of patients who
are carriers, as well as health systems because it is a high cost disease [19]. This
disease is one of the most frequent chronic diseases and has been increasing its
frequency in the last decade [20]. Only in the EU and the USA it affects about
5–6% of the population. Asthma and other forms of COPD require management,
self-management and monitoring in order to control the symptoms of the disease
with therapies adjusted to the condition of each patient and also to reduce the
risk of exacerbations [16, 20]. The vast majority of asthmatic patients undergo
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corticosteroid therapy by inhalation and with drugs called β-adrenergic agonists, and
a proportion of these patients require additional drugs such as oral corticosteroids
[20].
Some biological parameters are important both for the diagnosis of the disease,
as well as for its monitoring in the hospital environment and daily in the home.
Pulmonary function is a biological parameter that fits perfectly into this definition
[19].
The devices analysed are CareHomePod and HomePod, VITALS360® and
iSpO2®. All devices have the portability characteristic, enabling patients to use
them in the event of a need to travel. The iSpO2® is an adaptive device for an
android smartphone or iOS, which functions as a pulse oximeter [21]. In the case
of CareHomePod and HomePod the oximeter sends the values collected for these
devices through Bluetooth and the VITALS360® has a built-in oximeter. Again,
the processes of obtaining the values is not invasive in all devices and platforms.
Then, measured values are sent through Wi-Fi to databases. The data is analysed by
specialized health professionals who subsequently decide how to act. The interface
of the device to the patient is simple on all devices and customizable to the patient
[12, 21].
Table 2 reviews the technical specifications of the devices and telemonitoring
systems found for COPD and Asthma.
The comparative results present the same conclusions as in the case of diabetes
mellitus. Interoperability is the missing technical specification in the three devices
and systems of telemonitoring analysed.
3.3 Telemonitoring Systems Used in Chronic Kidney Disease
Chronic kidney disease is a progressive disease that irreversibly impairs kidney
structure and function [22].
Table 2 Comparison of technical specifications of telemonitoring devices used in DPOC and
Asthma




Portability Yes Yes Yes
Invasiveness No No No
Interface Custom and simple Custom and simple Custom and simple
Connectivity Bluetooth
Wi-Fi
Wi-Fi Direct connection to
smartphone
Wi-Fi
Interoperability No No No
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Chronic kidney disease is associated with high morbidity, mortality and also
high health expenditure. Factors such as diabetes mellitus, hypertension and car-
diovascular diseases may contribute to the onset of chronic kidney disease. Thus,
the prevalence of chronic kidney disease is increasing globally [23]. In the USA in
2006, the prevalence of chronic kidney disease in the adult population over 65 years
of age at stage 3 was estimated to be 7.6 million patients at stage 4 of 400,000
patients and at stage 5 of 300,000 patients [24].
Chronic kidney patients in the early stages of the disease may be asymptomatic,
leading to a lack of demand for medical care. Timely care of these patients can
lead to a reduction in morbidity, mortality, costs associated with the disease, as
well as a reduction in the number of consultations required for the patient, as the
responsiveness of health systems tends to decrease [25, 26].
The economic burden on health systems increases as the disease progresses,
with the greatest burden being on the last stage involving dialysis, hemodialysis or
renal transplantation. Avoiding reaching these stages is important. Controlling the
disease is fundamental, preventing its progression and consequently alleviating the
economic burden, minimizing hospitalizations and improving the patient’s quality
of life [27].
In some situations not reaching the last stage of the disease becomes impossible.
Peritoneal dialysis becomes the best solution for these patients. Telemonitoring
combined with dialysis becomes a fundamental point, thus increasing the bet in
this area [28].
In order to provide optimal care for these patients, telemonitoring becomes
an essential component of health systems in the care of chronic kidney patients
[25]. Telemonitoring combined with self-monitoring in these patients is essential in
preventing disease progression and consequently in reducing hospitalizations [26].
Many telemonitoring systems applied to chronic kidney disease are still under
development. In the following description of the devices, only the first device is
already on the market. With all the rest only case studies were done to see if they are
effective in the disease, having all had great success with proven effectiveness. The
systems described are EQ Connect™, eNephro and Prototype Device. All systems
present the portable advantage, enabling patients to use them aboard. This feature
is largely due to the fact that they are web and android applications that receive
the specific disease-related data predefined by specialized healthcare professionals
through the manual introduction of data by the patient. The measuring process
is non-invasive. The results are sent through Wi-Fi to databases to be analysed
by specialized health professionals. The device interface to the patient is simple
and customizable to the patient in the EQ Connect™ and eNephro application.
The Prototype Device (still in development) is not customizable to the patient
[24, 26, 29].
Table 3 reviews the technical specifications of telemonitoring systems found
for Chronic Kidney Disease. Again, the results are similar. Interoperability is the
missing technical specification in the three telemonitoring systems analysed.
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Table 3 Comparison of technical specifications of telemonitoring systems used in Chronic
Kidney Disease
Device 1 Device 2 Device 3
Designation EQ Connect™ eNephro Prototype device
Portability Yes Yes Yes
Invasiveness No No No
Interface Custom and simple Custom and simple Not customized and simple
Connectivity Wi-Fi Wi-Fi Wi-Fi
Interoperability No No No
3.4 Telemonitoring Devices Used in Thromboembolic Diseases
Thrombosis is a pathology characterized by excess blood clotting that exists in
vessel walls, thus becoming the desirable opposite of homeostasis, where there
is coagulation necessary at specific sites of vessels where there is injury. This
pathology occurs both in the arterial circulation and in the venous circulation and
can trigger different pathologies depending on where it occurs, such as myocardial
infarction, pulmonary embolism and ischemic stroke [30].
The possible thromboembolic events are prevented by therapeutic measures such
as oral anticoagulants, such as warfarin, and the aim of this therapy is to preserve
adjusted anticoagulation levels, preventing events with the lowest possible risk of
haemorrhage [31, 32].
The devices described are eCareCompanion, Genesis Telemonitor and Hon-
eywell HomMed. All systems are portable. Honeywell HomMed is the largest
platform, thus less easy to transport. Obtaining the INR value is invasive and is
performed by puncture to obtain a drop of blood that is placed on a test strip
previously placed in an INR monitoring device. In eCareCompanion the value of
INR is received via Bluetooth, in the case of Genesis Telemonitor the value is
entered manually and in Honeywell HomMed receives the data through a cable
connected to the INR monitoring device. Results are sent through Wi-Fi to databases
in order to be analysed by specialized health professionals. The patient-to-patient
interface is simple and customizable to the patient on all devices [33–35].
Table 4 reviews the technical specifications of devices and telemonitoring
systems found for thromboembolic diseases. As in the previous cases, the inter-
operability between systems and devices is not available.
3.5 Telemonitoring Devices Used in Heart Failure
Heart failure is a disease that is growing in developed countries, despite the
diminished incidence of cardiovascular diseases. It is estimated that there are 23
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Table 4 Comparison of technical specifications of telemonitoring systems used in Thromboem-
bolic Diseases
Device 1 Device 2 Device 3
Designation eCareCompanion Genesis Telemonitor Honeywell HomMed
Portability Yes Yes Yes/no
Invasiveness Yes Yes Yes









Interoperability No No No
Table 5 Comparison of technical specifications of telemonitoring systems used in Heart Failure
Device 1 Device 2 Device 3
Designation VITALS360® TCare cardio monitor Smartheart™
Portability Yes Yes Yes
Invasiveness No No No
Interface Custom and simple Custom and simple Custom and simple
Connectivity Wi-Fi Bluetooth GSM/HDSPA BluetoothWi-Fi
Interoperability No No No
million people living with the disease in the world [35, 36]. Due to the progression
of the disease, the decompensation is frequent, which leads to hospitalizations also
more frequent [37]. In the USA alone, the number of hospitalizations exceeds one
million per year, which significantly increases the costs associated with the disease
for both the patient and the health system [35]. According to Liu et al. [38, 39],
costs directly and indirectly involving the treatment of heart failure in the USA
were around $39.2 billion in 2010, with only re-hospitalizations accounting for
approximately $31 billion of dollars spent.
The devices described are VITALS360®, TCare Cardio Monitor and Smart-
heart™. All devices and systems are portable. Obtaining the ECG tracing is
non-invasive and is the main test performed with these devices and telemonitoring
systems. In VITALS360®, the ECG is performed directly on the device. In the
remaining devices, the ECG trace is sent via Bluetooth from external ECG devices.
Results are sent through Wi-Fi in the case of TCare Cardio Monitor through
GSM/HDSPA. The patient-to-patient interface is simple and customizable to the
patient on all devices [12, 40, 41].
Table 5 reviews the technical specifications of the devices and telemonitoring
systems found for Heart Failure. Following the path of the telemonitoring devices
for the previous pathologies, the interoperability between devices and systems of
different brands is inexistent.
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4 Proposal for Future Telemonitoring IoT System
The proposed trend-based telemonitoring system is shown in Fig. 1. This is
composed of four components (1) wearable monitoring device; (2) smartphone
(health application); (3) cloud; (4) call centre, patient and doctor.
The proposal considers a wearable and non-invasive device that is placed in con-
tact with the patient’s skin, acquires the indicated biological and physical parameters
for the disease in question. The proposed non-invasive wearable monitoring device
consists of one or more biological and physical parameter measurement sensors,
a microcontroller, a battery and a Bluetooth Low Energy (BLE) integrated circuit.
The data is collected by the monitoring device and sent to the smartphone via BLE.
In the smartphone there is a health application that collects and filters firstly
the data, according to an algorithm that limits the values. These limits should be
adjusted and personalized for each patient, being only sent to the cloud values
higher than the reference values. Inter-operation for the remote cloud-based system
could be helped by using common health data APIs/wellness data APIs (some of
which are already on the market) or health data description taxonomies (currently
a focus of research). In the cloud there is another algorithm that decides according
to the results received: (1) it communicates some message to the patient. If this
condition occurs, an information report is also sent to the specialist doctor who
follows the patient. (2) If it is sent to the call centre, the results are outside the limit
range and the medical specialists will decide what procedures to take, contact the
patient immediately giving instructions of procedures to take, contact the emergency
service to move to the patient or even contact the patient’s personal doctor to help
make a decision.
This ideal IoT telemonitoring system will be able to interoperate with programs
developed by different software houses, in order to allow the flow of information of
patients’ clinical data between healthcare systems at different levels, ensuring the
confidentiality and security of data.
Fig. 1 Scheme of the proposal for future IoT telemonitoring system
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5 Conclusions
Telemonitoring for chronic patients can bring great benefits to both the patient and
health systems. For the patient the increase of care in the self-management of the
disease consequently leads to an improvement in the health condition and quality of
life, for the health systems the distribution of resources is achieved in an equitable
way reaching the majority of possible chronic population.
The enlargement of this practice applied to chronic pathologies will be a reality
in the near future, not forgetting that until this premise becomes real some gaps will
have to be overcome as the creation of interoperability programs between health
support systems, which is the main failure of the devices and systems telemonitoring
existing on the market.
References
1. World Health Organization: Noncommunicable diseases. http://www.who.int/topics/
noncommunicable_diseases/en/. Accessed 04 Feb 2017
2. Ho, K.: Supporting heart failure patient transitions from acute to community care with
home telemonitoring technology: a protocol for a provincial randomized controlled trial
(TEC4Home). JMIR Res. Protoc. 5(4), e198 (2016)
3. Saner, H., Van Der Velde, E.: eHealth in cardiovascular medicine: a clinical update. Eur. J.
Prev. Cardiol. 23, 5–12 (2016)
4. Paré, G., Moqadem, K., Pineau, G., St-Hilaire, C.: Clinical effects of home telemonitoring in
the context of diabetes, asthma, heart failure and hypertension: a systematic review. J. Med.
Internet Res. 12(2), e21 (2010)
5. Esteban, C., Moraza, J., Iriberri, M., Aguirre, U., Goiria, B., Quintana, J.M., Aburto, M.,
Capelastegui, A.: Outcomes of a telemonitoring-based program (telEPOC) in frequently
hospitalized COPD patients. Int. J. COPD. 11, 2919–2930 (2016)
6. Bashshur, R.L., Shannon, G.W., Smith, B.R., Alverson, D.C., Antoniotti, N., et al.: The
empirical foundations of telemedicine interventions for chronic disease management. Telemed.
J. E Health. 20, 769–800 (2014)
7. Gyllensten, I.C., Crundall-Goode, A., Aarts, R.M., Goode, K.M.: Simulated case management
of home telemonitoring to assess the impact of different alert algorithms on work-load and
clinical decisions. BMC Med. Inform. Decis. Mak. 17(1), 11 (2017)
8. Craig, M.E., Hattersley, A., Donaghue, K.C.: Definition, epidemiology and classification of
diabetes in children and adolescents. Pediatr. Diabetes. 15, 4–17 (2014)
9. Cariou, B., Eddy, D., Schwarz, P., Gumprecht, J., Smith, U., et al.: The diabetes epidemic and
its impact on Europe. In: European Diabetes Leadership Forum, p. 44. OECD, Paris (2012)
10. Wild, S.H., Hanley, J., Lewis, S.C., McKnight, J.A., McCloughan, L.B., et al.: Supported
telemonitoring and glycemic control in people with type 2 diabetes: the telescot diabetes
pragmatic multicenter randomized controlled trial. PLoS Med. 13, 1–16 (2016)
11. Edevice: HealthGO Mini. http://www.edevice.com/products/healthgo-mini. Accessed 08 Jun
2017
12. VoCare: Vitals360®. http://vocare.com/vitals360/. Accessed 06 Jun 2017
13. TelehealthSolutions: CareHomePod. https://www.thsl.co.uk/products/carehomepod. Accessed
08 Jun 2017
14. VoCare®. Vitals360® user manual. p. 13 (2013)
dinis@ubi.pt
86 L. T. Machadeiro et al.
15. Pedone, C., Lelli, D.: Systematic review of telemonitoring in copd: an update. Pneumonol.
Alergol. Pol. 83, 476–484 (2015)
16. Vivekanandan, S., Devanand, M.: Remote monitoring for diabetes disorder: pilot study using
InDiaTel prototype. Eur. Res. Telemed. 4, 63–69 (2015)
17. Fitzsimmons, D.A., Thompson, J., Bentley, C.L., Mountain, G.A.: Comparison of patient
perceptions of Telehealth-supported and specialist nursing interventions for early stage COPD:
a qualitative study. BMC Health Serv. Res. 16, 420 (2016)
18. Merone, M., Pedone, C., Capasso, G., Incalzi, R.A., Soda, P.: A decision support system for
tele-monitoring COPD-related worrisome events. IEEE J. Biomed. Health Informatics. 2194,
2168–2194 (2017)
19. Mulpuru, S., Mckay, J., Ronksley, P.E., Thavorn, K., Kobewka, D.M., Forster, A.J.: Factors
contributing to high-cost hospital care for patients with COPD. Int. J. COPD. 12, 989–995
(2017)
20. Fonseca, J.A., Costa-Pereira, A., Delgado, L., Silva, L.N., Magalhães, M., Castel-Branco,
M.G., Vaz, M.: Pulmonary function electronic monitoring devices: a randomized agreement
study. Chest J. 128, 1258–1265 (2005)
21. Masimo: iSpO2® pulse oximeter. http://masimopersonalhealth.com/products/ispo2-pulse-
oximeter/. Accessed 07 Jun 2017
22. Masimo Shop. http://masimopersonalhealth.com/shop/. Accessed 07 Jun 2017
23. Wilson, C., Campbell, S.M., Luker, K.A., Caress, A.L.: Referral and management options
for patients with chronic kidney disease: perspectives of patients, generalists and specialists.
Health Expect. 18, 325–334 (2015)
24. Cuevas, J.R., Dominguez, E.L., Velazquez, Y.H.: Telemonitoring system for patients with
chronic kidney disease undergoing peritoneal dialysis. IEEE Lat. Am. Trans. 14, 2000–2006
(2016)
25. Raman, M., Green, D., Middleton, R.J., Kalra, P.A.: Older people with chronic kidney
disease: definition, and influence of biomarkers and medications upon cardiovascular and renal
outcomes. J. Ren. Care. 42, 150–161 (2016)
26. Thilly, N., Chanliau, J., Frimat, L., Combe, C., Merville, P., et al.: Cost-effectiveness of home
telemonitoring in chronic kidney disease patients at different stages by a pragmatic randomized
controlled trial (eNephro): rationale and study design. BMC Nephrol. 18, 126 (2017)
27. Singh, P., Ricksten, S.E., Bragadottir, G., Redfors, B., Nordquist, L.: Renal oxygenation and
haemodynamics in acute kidney injury and chronic kidney disease. Clin. Exp. Pharmacol.
Physiol. 40, 138–147 (2013)
28. Trifirò, G., Fatuzzo, P.M., Ientile, V., Pizzimenti, V., Ferrajolo, C., et al.: Expert opinion of
nephrologists about the effectiveness of low-protein diet in different stages of chronic kidney
disease (CKD). Int. J. Food Sci. Nutr. 65, 1027–1032 (2014)
29. eQOL: Our solutions empower patients to manage their care outside of the hospital. https://
eqol.ca/index.php (2017). Accessed 11 Jun 2017
30. Jeffs, L., Jain, A.K., Man, R.H., Onabajo, N., Desveaux, L., et al.: Exploring the utility and
scalability of a telehomecare intervention for patients with chronic kidney disease undergoing
peritoneal dialysis—a study protocol. BMC Nephrol. 18, 155 (2017)
31. Kenne, E., Nickel, K.F., Long, A.T., Fuchs, T.A., Stavrou, E.X., et al.: Factor XII: a novel target
for safe prevention of thrombosis and inflammation. J. Intern. Med. 278, 571–585 (2015)
32. Araújo, A.C.O., Domingues, R.B., van Bellen, B.: Determinação do INR: Comparação entre
método convencional e dispositivo portátil. J. Vasc. Bras. 13, 88–93 (2014)
33. Philips: eCareCompanion patient app. http://www.usa.philips.com/healthcare/product/
HCNOCTN483/ecarecompanion-patient-app-your-patients-gateway-to-care. Accessed 09 Jun
2017
34. Honeywell Life Care: Genesis telemonitor – targeted solution. https://
www.honeywelllifecare.com/lifestream-products/legacy-products-and-software/genesis-
telemonitor/. Accessed 09 Jun 2017
35. Pyramidhhs. http://pyramidhhs.com/index.php/services/home-health/missouri-telemonitoring-
remote-disease-management. Accessed 09 Jun 2017
dinis@ubi.pt
Telemonitoring Devices and Systems: Current Status and Future Trends 87
36. Pyramid HHS. http://pyramidhhs.com/index.php/contact-us. Accessed 09 Jun 2017
37. Tadic, M., Pieske-Kraigher, E., Cuspidi, C., Genger, M., Morris, D.A., et al.: Left ventricular
strain and twisting in heart failure with preserved ejection fraction: an updated review. Heart
Fail. Rev. 22, 371–379 (2017)
38. Knox, L., Rahman, R.J., Beedie, C.: Quality of life in patients receiving telemedicine enhanced
chronic heart failure disease management: a meta-analysis. J. Telemed. Telecare. 23(7), 639–
649 (2017)
39. Pazos-López, P., Peteiro-Vázquez, J., Carcía-Campos, A., García-Bueno, L., de Torres, J.P.A.,
Castro-Beiras, A.: The causes, consequences, and treatment of left or right heart failure. Vasc.
Health Risk Manag. 7, 237–254 (2011)
40. TCare Cardio Monitor. http://www.tcare.pt/servicos/tcare-cardio-monitor/. Accessed 04 Jun
2017
41. SHL Telemedicine: SmartHeart. http://www.shl-telemedicine.com/portfolio/smartheart/.
Accessed 08 Jun 2017
